NCT00527891

Brief Summary

Primary Objective: 1\. To compare the efficacy of 1.5T vs. 3T T1 and T2-weighted MR images sequences for the detection and evaluation of liver lesions.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2004

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2007

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

September 10, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 11, 2007

Completed
Last Updated

July 31, 2012

Status Verified

July 1, 2012

Enrollment Period

3.3 years

First QC Date

September 10, 2007

Last Update Submit

July 30, 2012

Conditions

Liver Cancer

Keywords

Liver CancerMagnetic Resonance ImagingSigna Excite 3.0T MRI Scan

Study Arms (1)

Signa Excite 3.0 T MRI Scan

Signa Excite 3.0 T MRI Scan

Procedure: Signa Excite 3.0 T MRI Scan

Interventions

Signa Excite 3.0 T MRI ScanPROCEDURE

Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.

Signa Excite 3.0 T MRI Scan

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients scheduled and are eligible for an MRI of the abdomen or MRI of the liver or MRI of the kidney examination at UT MD Anderson Cancer Center.

You may qualify if:

  • Patients with a liver lesion larger than 1cm detected by a prior imaging modality.
  • Patients have been scheduled and are eligible for an MRI of the abdomen or MRI of the liver or MRI of the kidney examination.

You may not qualify if:

  • \) Patients who are unable to cooperate with breath hold.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

U.T.M.D. Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Liver Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver Diseases

Study Officials

  • Janio Szklaruk, MD

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2007

First Posted

September 11, 2007

Study Start

June 1, 2004

Primary Completion

September 1, 2007

Last Updated

July 31, 2012

Record last verified: 2012-07

Locations

US(1)